TY  - CHAP
M1  - Book, Section
TI  - Basic Principles of Neuropharmacology
A1  - Nestler, Eric J.
A1  - Kenny, Paul J.
A1  - Russo, Scott J.
A1  - Schaefer, Anne
PY  - 2020
T2  - Nestler, Hyman & Malenka’s Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, 4e
AB  - KEY  CONCEPTSAn  understanding  of  drug  mechanisms  in  the  brain  must  integrate  knowledge  of  the  molecular  and  cellular  actions  of  a  drug  with  their  effects  on  brain  circuitry.The  clinical  actions  of  a  drug  in  the  brain  often  are  due  to  neural  plasticity—the  long–term  adaptations  of  neurons  or  other  cell  types  to  the  sustained  short–term  actions  of  a  drug.The  binding  of  a  drug  to  its  specific  target(s)  normally  is  saturable  and  stereoselective.The  specific  binding  of  a  drug  to  its  target  is  quantified  according  to  its  affinity  for  the  target,  expressed  as  a  dissociation  constant  (Kd),  and  the  total  amount  of  binding  (Bmax).Potency  of  a  drug  describes  the  strength  of  binding  between  the  drug  and  its  target;  efficacy  describes  the  maximal  biologic  effects  that  the  drug  exerts  by  binding  to  its  target.Drugs  that  act  at  receptors  can  be  classified  as  agonists,  partial  agonists,  biased  agonists,  inverse  agonists,  antagonists,  positive  allosteric  modulators,  or  negative  allosteric  modulators.Modern  neuropharmacology  takes  advantage  of  the  tools  of  molecular  biology,  genetics,  and  cell  biology  as  well  as  combinatorial  chemistry,  which  is  used  to  generate  novel  molecules  that  may  function  as  new  drugs.Functional  genomics  and  proteomics  will  help  identify  novel  drug  targets.Pharmacogenetics  will  guide  the  choice  of  drug  treatments  based  on  an  individual’s  genetic  constitution.  
SN  - 
PB  - McGraw-Hill
CY  - New York, NY
Y2  - 2024/04/20
UR  - neurology.mhmedical.com/content.aspx?aid=1174972895
ER  -